Michal Piotr Marszall
Overview
Explore the profile of Michal Piotr Marszall including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
279
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chalupka J, Marszall M, Sikora A
Int J Mol Sci
. 2024 Oct;
25(19).
PMID: 39409060
This study aimed to optimize the kinetic resolution of building blocks for the synthesis of β-blockers using lipases, which could be potentially used to synthesize enantiomerically pure β-blockers further. Reaction...
2.
Siodmiak J, Duleba J, Kocot N, Mastalerz R, Haraldsson G, Marszall M, et al.
Int J Mol Sci
. 2024 May;
25(10).
PMID: 38791124
The use of lipase immobilized on an octyl-agarose support to obtain the optically pure enantiomers of chiral drugs in reactions carried out in organic solvents is a great challenge for...
3.
Chalupka J, Sikora A, Ziegler-Borowska M, Marszall M
Int J Mol Sci
. 2023 Jul;
24(13).
PMID: 37446300
Clopidogrel is a chiral compound widely used as an antiplatelet medication that lowers the risk of blood clots, strokes, and heart attacks. The main aim of the study presented herein...
4.
Niezgoda P, Baranska M, Adamski P, Pietrzykowski L, Marszall M, Wojakowski W, et al.
Cardiol J
. 2021 Oct;
29(2):324-328.
PMID: 34642919
No abstract available.
5.
Kubica J, Adamski P, Buszko K, Baranska M, Sikora J, Marszall M, et al.
Eur Heart J Cardiovasc Pharmacother
. 2019 Jan;
5(3):139-148.
PMID: 30689800
Aims: Currently available data indicate that reduction of ticagrelor maintenance dose (MD) 1-3 years after acute myocardial infarction (AMI) not only provides sufficient platelet inhibition but also can improve ticagrelor's...
6.
Sikora J, Niezgoda P, Baranska M, Buszko K, Skibinska N, Sroka W, et al.
Thromb Haemost
. 2018 Nov;
118(12):2126-2133.
PMID: 30453344
Extensive search for methods of overcoming morphine-related delay of the absorption and onset of action of oral P2Y inhibitors in patients presenting with acute coronary syndrome is on-going. The aim...
7.
Sikora J, Pstragowski K, Skibinska N, Sobczak P, Sikora A, Marszall M, et al.
Thromb Res
. 2017 Oct;
159:76-81.
PMID: 28987709
Levosimendan has been developed for treatment of severe heart failure. The favorable hemodynamic effect of levosimendan is related to its unique dual mechanism of action - increase of the contractile...
8.
Adamski P, Ostrowska M, Sikora J, Obonska K, Buszko K, Krintus M, et al.
BMJ Open
. 2017 Apr;
7(4):e013218.
PMID: 28446521
Introduction: The most common classification of acute myocardial infarction (AMI) is based on electrocardiographic findings and distinguishes ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI). Both types of AMI...
9.
Niezgoda P, Sikora J, Baranska M, Sikora A, Buszko K, Sieminska E, et al.
Thromb Haemost
. 2017 Feb;
117(4):718-726.
PMID: 28203684
Oral administration of crushed ticagrelor tablets turned out to be an efficacious method that improves its pharmacokinetics and pharmacodynamics. This strategy, however, is unlikely to eliminate the drug-drug interaction in...
10.
Kozinski M, Ostrowska M, Adamski P, Sikora J, Sikora A, Karczmarska-Wodzka A, et al.
Thromb Haemost
. 2016 Sep;
116(6):1140-1149.
PMID: 27628615
Aim of this study was assessment of the relationship between concentrations of ticagrelor and its active metabolite (AR-C124910XX) and results of selected platelet function tests. In a single-centre, cohort study,...